Dose selection in phase I clinical trials in oncology
- At: 2017 FIP Congress in Stockholm (Sweden)
- Type: Presentation
- By: SCHELLENS, Jan (Netherlands Cancer Institute & University Utrecht, Clinical Pharmacology, Amsterdam, Netherlands)
- Co-author(s): Jan HM Schellens: Clinical Pharmacology, Netherlands Cancer Institute & University Utrecht, Amsterdam, Netherlands
Phase I studies in oncology are often carried out in patients with advanced cancer with the aim the select a safe dose and schedule for further testing in later phase II and III studies. Selection of the wrong dose and schedule can kill a good drug, which is a waist for patients and the pharmaceutical industry. Cabozantonib is a RET inhibitor.. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.